0.739
0.01 (1.23%)
| Penutupan Terdahulu | 0.730 |
| Buka | 0.720 |
| Jumlah Dagangan | 65,982 |
| Purata Dagangan (3B) | 95,725 |
| Modal Pasaran | 46,412,384 |
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 5.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Keuntungan | -45.59% |
| Margin Operasi (TTM) | -44.54% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 185.50% |
| Nisbah Semasa (MRQ) | 2.61 |
| Aliran Tunai Operasi (OCF TTM) | -13.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.67 M |
| Pulangan Atas Aset (ROA TTM) | -20.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -96.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Cytosorbents Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 15.29% |
| % Dimiliki oleh Institusi | 27.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avenir Corp | 30 Sep 2025 | 5,082,838 |
| Sargent Investment Group, Llc | 30 Sep 2025 | 738,700 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (D. Boral Capital, 1,253.18%) | Beli |
| Median | 5.38 (628.01%) | |
| Rendah | 0.750 (HC Wainwright & Co., 1.49%) | Pegang |
| Purata | 5.38 (628.01%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 0.660 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 14 Nov 2025 | 10.00 (1,253.18%) | Beli | 0.660 |
| 16 Sep 2025 | 10.00 (1,253.18%) | Beli | 0.909 | |
| HC Wainwright & Co. | 14 Nov 2025 | 0.750 (1.49%) | Pegang | 0.660 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2025 | Pengumuman | Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London |
| 13 Nov 2025 | Pengumuman | CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 11 Nov 2025 | Pengumuman | CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London |
| 30 Oct 2025 | Pengumuman | CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights |
| 29 Sep 2025 | Pengumuman | CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen |
| 16 Sep 2025 | Pengumuman | CytoSorbents Provides DrugSorb-ATR Regulatory Update |
| 08 Sep 2025 | Pengumuman | CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |